Antibodies binding to trimeric TNF alpha epitopes

Patent metadata

Field	Value
Publication number	US-11022614-B2
Application number	US-201515736558-A
Country	US
Kind code	B2
Filing date	Oct 22, 2015
Priority date	Jun 18, 2015
Publication date	Jun 1, 2021
Grant date	Jun 1, 2021

Abstract

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

First claim

The invention claimed is:

1. An antibody that binds to an epitope on trimeric TNFα comprising residues:
(a) L94 and P113;
(b) L94 and Y115; or
(c) P113 and Y115;

wherein L94 is present on the A subunit of the TNFα trimer, and P113 and Y115 are present on the C subunit of the TNFα trimer and wherein the residue numbering is according to SEQ ID NO: 36, wherein the antibody comprises:
(i) a HCDR1/HCDR2/HCDR3 sequence combination selected from SEQ ID NOs: 4/5/6 and SEQ ID NOs: 19/20/21, and a LCDR1/LCDR2/LCDR3 sequence combination selected from SEQ ID NOs: 1/2/3 and SEQ ID NOs: 1/17/18; or
(ii) a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/1/2/3 or SEQ ID NOs: 19/20/21/1/17/18.

2. The antibody according to claim 1 , which binds to an epitope comprising all three of L94, P113 and Y115, wherein L94 is present on the A subunit of the TNFα trimer and P113 and Y115 are present on the C subunit of the TNFα trimer.

3. The antibody according to claim 1 , which binds to an epitope further comprising:
(a) one or more residues selected from the following, which residues are present on the A subunit of the TNFα trimer: T77; T79; Y87; T89; K90; V91; N92; L93; S95; A96; 197; E135; I136; and R138; or
(b) one or more residues selected from the following, which residues are present on the C subunit of the TNFα trimer: L63; D143; F144; S147; and Q149,

wherein the numbering is according to SEQ ID NO: 36.

4. The antibody according to claim 1 , which binds to an epitope further comprising:
(a) one or more residues selected from the following, which residues are present on the A subunit of the TNFα trimer: L75; S81; R82; I83; I97; and D140; or
(b) one or more residues selected from the following, which residues are present on the C subunit of the TNFα trimer: P20; F64; and K65,

wherein the residue numbering is according to SEQ ID NO: 36.

5. The antibody according to claim 1 , which binds to an epitope further comprising the following residues:
(a) T77, T79, Y87, T89, K90, V91, N92, L93, S95, A96, I97, E135, I136 and R138, which residues are present on the A chain of the TNFα trimer;
(b) T77, T79, Y87, T89, K90, V91, N92, L93, S95, A96, I97, E135, I136, R138, L75, S81, R82, I83, I97 and D140, which residues are present on the A subunit of the TNFα trimer;
(c) L63, D143, F144, S147 and Q149, which residues are present on the C subunit of the TNFα trimer;
(d) L63, D143, F144, S147, Q149, P20, F64 and K65, which residues are present on the C subunit of the TNFα trimer;
(e) T77, T79, Y87, T89, K90, V91, N92, L93, S95, A96, I97, E135, I136 and R138, which residues are present on the A subunit of the TNFα trimer, and L63, D143, F144, S147 and Q149, which residues are present on the C subunit of the TNFα trimer; or
(f) T77, T79, Y87, T89, K90, V91, N92, L93, S95, A96, I97, E135, I136, R138, L75, S81, R82, I83, I97 and D140, which residues are present on the A subunit of the TNFα trimer, and L63, D 143, F144, S147, Q149, P20, F64 and K65, which residues are present on the C subunit of the TNFα trimer,

wherein the residue numbering is according to SEQ ID NO: 36.

6. The antibody according to claim 1 , which:
(a) has an affinity (K D-ab ) of 1 nM or less;
(b) has an affinity of 200 pM or less;
(c) is a humanized antibody; or
(d) is a Fab, modified Fab, Fab′, modified Fab′, F(ab′) 2 , Fv, single domain antibody or an scFv.

7. The antibody of claim 1 , wherein the antibody comprises at least three HCDRs selected from SEQ ID NOS:4-6.

8. The antibody of claim 1 , wherein the antibody comprises at least three HCDRs selected from SEQ ID NOS:19-21.

9. The antibody of claim 7 , wherein the antibody comprises three HCDRs comprising SEQ ID NO:4 for HCDR1, SEQ ID NO:5 for HCDR2 and SEQ ID NO:6 for HCDR3 and three LCDRs comprising SEQ ID NO:1 for LCDR1, SEQ ID NO:2 for LCDR2 and SEQ ID NO:3 for LCDR3.

10. The antibody of claim 8 , wherein the antibody comprises three HCDRs comprising SEQ ID NO:19 for HCDR1, SEQ ID NO:20 for HCDR2 and SEQ ID NO:21 for HCDR3, and three LCDRs comprising SEQ ID NO:1 for LCDR1, SEQ ID NO:17 for LCDR2 and SEQ ID NO:18 for LCDR3.

11. An antibody which binds to an epitope on trimeric TNFα comprising residues:
(a) L94 and P113;
(b) L94 and Y115; or
(c) P113 and Y115;

wherein L94 is present on the A subunit of the TNFα trimer, and P113 and Y115 are present on the C subunit of the TNFα trimer and wherein the residue numbering is according to SEQ ID NO: 36, wherein the antibody comprises a heavy chain variable region (HCVR) comprising SEQ ID NO:8 or 23 or comprising a sequence with more than 90% identity to SEQ ID NO:8 or 23 and a light chain variable region (LCVR) comprising SEQ ID NO:7 or 22 or comprising a sequence with more than 90% identity to SEQ ID NO:7 or 22,
wherein the sequence with more than 90% identity to SEQ ID NO:8 or 23 comprises
(i) HCDR1/HCDR2/HCDR3 sequences consisting of SEQ ID NOs: 4/5/6 and the remainder of the HCVR comprises more than 90% identity to SEQ ID NOs: 8 or 23, or
(ii) HCDR1/HCDR2/HCDR3 sequences consisting of SEQ ID NOs: 19/20/21 and the remainder of the HCVR comprises more than 90% identity to SEQ ID NOs: 8 or 23; and

wherein the sequence with more than 90% identity to SEQ ID NO:7 or 22 comprises
(i) LCDR1/LCDR2/LCDR3 sequences consisting of SEQ ID NOs: 1/2/3 and the remainder of the heavy and light chains comprise more than 90% identity to SEQ ID NOs: 7 or 22, or
(ii) LCDR1/LCDR2/LCDR3 sequences consisting of SEQ ID NOs: 1/17/18 and the remainder of the heavy and light chains comprise more than 90% identity to SEQ ID NOs: 7 or 22.

12. The antibody of claim 11 , wherein the antibody comprises an HCVR comprising SEQ ID NO:8 or comprising a sequence with more than 90% identity to SEQ ID NO:8 and an LCVR comprising SEQ ID NO:7 or comprising a sequence with more than 90% identity to SEQ ID NO:7.

13. The antibody of claim 11 , wherein the antibody comprises an HCVR comprising SEQ ID NO:23 or comprising a sequence with more than 90% identity to SEQ ID NO:23 and an LCVR comprising SEQ ID NO:22 or comprising a sequence with more than 90% identity to SEQ ID NO:22.

14. An antibody which binds to an epitope on trimeric TNFα comprising residues:
(a) L94 and P113;
(b) L94 and Y115; or
(c) P113 and Y115;

wherein L94 is present on the A subunit of the TNFα trimer, and P113 and Y115 are present on the C subunit of the TNFα trimer and wherein the residue numbering is according to SEQ ID NO: 36, wherein the antibody comprises a heavy chain comprising SEQ ID NO:12 or 13 or comprises heavy chain with more than 90% identity to SEQ ID NO:12 or 13, and a light chain comprising SEQ ID NO:11 or comprises a light chain with more than 90% identity to SEQ ID NO:11,
wherein the sequences that with more than 90% identity comprise:
(i) HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consisting of SEQ ID NOs: 4/5/6/1/2/3 and the remainder of the heavy and light chains comprise more than 90% identity to SEQ ID NOs: 12 and 11, respectively; or
(ii) HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consisting of SEQ ID NOs: 4/5/6/1/2/3 and the remainder of the heavy and light chains comprise more than 90% identity to SEQ ID NOs: 13 and 11, respectively.

15. An antibody which binds to an epitope on trimeric TNFα comprising residues:
(a) L94 and P113;
(b) L94 and Y115; or
(c) P113 and Y115;

wherein L94 is present on the A subunit of the TNFα trimer, and P113 and Y115 are present on the C subunit of the TNFα trimer and wherein the residue numbering is according to SEQ ID NO: 36, wherein the anti

Assignees

• UCB Biopharma SRL
• Sanofi Sa

Inventors

• O'Connell James Philip
• Porter John Robert
• Lawson Alastair
• Arakaki Tracy Lynn
• Lightwood Daniel John
• Munro Rebecca Jayne

Classifications

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title

• G01N2333/7151

  for tumor necrosis factor [TNF]; for lymphotoxin [LT] · CPC title

• G01N2333/525

  Tumor necrosis factor [TNF] · CPC title

• G01N33/6863

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title